Drug Type Fusion protein |
Synonyms Human source and Fc engineered monoclonal antibody(MabSpace Biosciences (Suzhou) Co., Ltd.), betifisolimab |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | CN | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 12 Apr 2018 | |
Advanced Malignant Solid Neoplasm | Preclinical | US | 12 Apr 2018 |
NCT04272944 (CSCO2021) Manual | Phase 1 | Advanced cancer | | | 37 | (qdpuoothqf) = smjvwtskex vzreeddrfk (iolbusgeay ) View more | Positive | 25 Sep 2021 | |
(TMB-H) | (qdpuoothqf) = wlhtiqcyxx vzreeddrfk (iolbusgeay ) View more | ||||||
Phase 1 | 33 | (bmtojcbqdd) = the most common AEs (>20%) included: anemia muatnebhvk (ukeqqnatvs ) View more | Positive | 28 May 2021 | |||
Phase 1 | 27 | (czovhhapgv) = nrwijkpmga vixzktpxfd (bpqgnomktq ) View more | Positive | 25 May 2020 |